Lei Gao

Lei Gao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
TGTangke Gao
Tangke Gao
SHShaopu Hu
Shaopu Hu
MJMin Jiang
Min Jiang
GOGuangyin Ou
Guangyin Ou
RZRuikang Zhong
Ruikang Zhong
LGLei Gao
Lei Gao
Huayu Wan (HYW), a traditional Chinese medicine prescription widely used in the clinical treatment of advanced lung cancer, has been clinically proven to effectively inhibit the progression of pulmonary tumors and improve patients' quality of life. However, its specific components and potential anti-cancer molecular mechanisms remain unclear. To explore the active ingredients of HYW and predict its effective targets and pathways against non-small cell lung cancer (NSCLC) using a combination of network pharmacology and transcriptomics. These predictions were subsequently validated through in vitro and in vivo experiments, providing a theoretical basis for its anti-cancer mechanism. We first established a LEWIS tumor-bearing mouse model to evaluate the dose-response relationship and inhibitory effect of HYW in NSCLC. Using Ultra-High Performance Liquid Chromatography-Quadrupole-Orbitrap-High Resolution Mass Spectrometry (UHPLC-Q-Orbitrap-HRMS), we comprehensively explored the material basis of HYW's therapeutic effect on lung cancer. Combining network pharmacology and transcriptomics, we further verified the potential molecular targets and pathways of HYW. Finally, in vitro and in vivo molecular biological experiments were conducted to validate the predicted results. HYW exhibited a dose-dependent tumor inhibitory effect in the LEWIS tumor-bearing mouse model. Comprehensive qualitative analysis of the chemical components of HYW through UHPLC-Q-Orbitrap HRMS identified 39 major active ingredients, including geniposide, quercetin, taurine, and paeoniflorin. The constructed HYW active compound-NSCLC target network revealed 48 core targets, which may play a critical role in HYW's anti-NSCLC therapeutic effects. Combining transcriptomic data from mouse tumor tissues, four core targets-Pik3ca, Akt1, Pdk1, and VEGFA-were identified, along with the key signaling pathway PI3K/AKT/VEGFA. Immunofluorescence results indicated that HYW dose-dependently inhibited the positive expression of Ki67 in mouse tumor tissues. In vitro experiments showed that HYW significantly suppressed the proliferation, migration, and invasion abilities of H1299 and A549 cells. qRT-PCR and Western blot analyses demonstrated that HYW treatment downregulated the expression of Pik3ca, Akt1, Pdk1, and VEGFA, and inhibited the protein expression levels of p-PI3K/PI3K, p-AKT/AKT, and VEGFA. HYW effectively inhibits the malignant proliferation of NSCLC cells. The mechanism of its anti-cancer effects is likely mediated by the suppression of the PI3K/AKT/VEGFA signaling pathway. This finding provides new molecular insights into the potential therapeutic application of HYW in the treatment of lung cancer.

2 February 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
RZRuikang Zhong
Ruikang Zhong
TGTangke Gao
Tangke Gao
JLJinghua Li
Jinghua Li
ZLZexing Li
Zexing Li
XTXue Tian
Xue Tian
KHKaiwen Hu
Kaiwen Hu
Background: Lung cancer (LC) is the second-highest incidence and the first-highest mortality cancer worldwide. Early screening and precise treatment of LC have been the research hotspots in this field. Artificial intelligence (AI) technology has advantages in many aspects of LC and widely used such as LC early diagnosis, LC differential classification, treatment and prognosis prediction.Objective: This study aims to analyze and visualize the research history, current status, current hotspots, and development trends of artificial intelligence in the field of lung cancer using bibliometric methods, and predict future research directions and cutting-edge hotspots.Results: A total of 2931 articles published between 2003 and 2023 were included, contributed by 15,848 authors from 92 countries/regions. Among them, China (40%) with 1173 papers,USA (24.80%) with 727 papers and the India(10.2%) with 299 papers have made outstanding contributions in this field, accounting for 75% of the total publications. The primary research institutions were Shanghai Jiaotong University(n=66),Chinese Academy of Sciences (n=63) and Harvard Medical School (n=52).Professor Qian Wei(n=20) from Northeastern University in China were ranked first in the top 10 authors while Armato SG(n=458 citations) was the most co-cited authors. Frontiers in Oncology(121 publications; IF 2022,4.7; Q2) was the most published journal. while Radiology (3003 citations; IF 2022, 19.7; Q1) was the most co-cited journal. different countries and institutions should further strengthen cooperation between each other. The most common keywords were lung cancer, classification, cancer, machine learning and deep learning. Meanwhile, The most cited papers was Nicolas Coudray et al.2018.NAT MED(1196 Total Citations).Conclusions: Research related to AI in lung cancer has significant application prospects, and the number of scholars dedicated to AI-related research on lung cancer is continually growing. It is foreseeable that non-invasive diagnosis and precise minimally invasive treatment through deep learning and machine learning will remain a central focus in the future. Simultaneously, there is a need to enhance collaboration not only among various countries and institutions but also between high-quality medical and industrial entities.

30 December 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
XTXue Tian
Xue Tian
GOGuangyin Ou
Guangyin Ou
SHShaopu Hu
Shaopu Hu
CWChunhui Wang
Chunhui Wang
FHFei Han
Fei Han
LGLei Gao
Lei Gao

30 March 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
SHShaopu Hu
Shaopu Hu
MGMengxue Ge
Mengxue Ge
SZShuixiu Zhang
Shuixiu Zhang
MJMin Jiang
Min Jiang
KHKaiwen Hu
Kaiwen Hu
LGLei Gao
Lei Gao
Background: Hedysarum Multijugum Maxim–Curcumae Rhizoma (HMMCR), a well-known herb pair in traditional Chinese medicine (TCM), has been widely used for the treatment of various cancers. However, the active components of HMMCR and the underlying mechanism of HMMCR for non-small-cell lung carcinoma (NSCLC) remain unclear.Methods: Active ingredients of HMMCR were detected by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). On this basis, potential targets of HMMCR were obtained from SwissTargetPrediction database. NSCLC-related targets were collected from four public databases (GeneCards, OMIM, TTD, and PharmGkb). The drug ingredients–disease targets network was visualized. The hub targets between HMMCR and NSCLC were further analyzed by protein–protein interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Subsequently, the results predicted by network pharmacology were further validated via in vitro experiments.Results: A total of 181 compounds were identified from the aqueous extract of HMMCR. Through network analysis, a compound–target network including 153 active ingredients of HMMCR and 756 HMMCR-NSCLC co-targets was conducted; 6 crucial compounds and 62 hub targets were further identified. The results of KEGG enrichment analysis showed that PI3K/Akt signaling pathway may be the critical pathway of HMMCR in the treatment of NSCLC. The in vitro experiments indicated that HMMCR inhibits the proliferation and migration of NSCLC cells via inactivation of the PI3K/Akt signaling pathway, consistent with the results predicted by network pharmacology.Conclusion: Integrating LC-ESI-MS/MS, network pharmacology approach, and in vitro experiments, this study shows that HMMCR has vital therapeutic effect on NSCLC through multi-compound, multi-target, and multi-pathway, which provides a rationale for using HMMCR for the treatment of NSCLC.

26 April 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GOGuangyin Ou
Guangyin Ou
TGTangke Gao
Tangke Gao
SHShaopu Hu
Shaopu Hu
SZShuixiu Zhang
Shuixiu Zhang
SSShuo Song
Shuo Song
MJMin Jiang
Min Jiang
Chordin-like 1 (CHRDL1) is a secreted antagonist of bone morphogenetic proteins, and has been implicated in various biological processes and cancer prognosis. This study offered a detailed examination of CHRDL1 expression across 33 diverse cancer types, leveraging data from The Cancer Genome Atlas (TCGA) and supplementary public datasets. We demonstrated that, for the majority of cancer types, CHRDL1 expression was reduced in tumor tissues compared to normal adjacent tissues. Notably, lower CHRDL1 expression led to negative prognosis in malignancies such as lung adenocarcinoma (LUAD), melanoma (SKCM), and mesothelioma (MESO). Furthermore, CHRDL1 expression was positively correlated with the infiltration of CD4⁺ T cells, CD8⁺ T cells, B cells, neutrophils, macrophages, and dendritic cells in most tumors. Higher CHRDL1 expression correlated with more favorable immune profiles and a reduction in tumor stemness. To assess the effect of CHRDL1 overexpression on LUAD progression, we conducted CCK-8, wound healing, and invasion assays in vitro, along with subcutaneous tumor formation experiments in nude mice. The results showed that the proliferation, migration, and invasion abilities of A549 and H1299 cells with high CHRDL1 expression were reduced, and the growth of A549 cells was also significantly inhibited in nude mice. These findings underscored CHRDL1’s potential as a prognostic biomarker and its influence on tumor immunology and cellular dynamics.

28 August 2026 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
RZRuikang Zhong
Ruikang Zhong
DLDianna Liu
Dianna Liu
YDYuewen Dai
Yuewen Dai
ZLZexing Li
Zexing Li
ZSZilin Song
Zilin Song
KHKaiwen Hu
Kaiwen Hu
Traditional Chinese Medicine (TCM) clinical practice depends on both codified theoretical knowledge and practitioner-specific experience, which differ in their data sources, reasoning patterns, and scope of generalization. We developed DFGLM-TCM, a modular large language model-based service system that separately models these two knowledge types through task-oriented components and coordinates them within a unified multi-task architecture. The knowledge-oriented component integrated a curated 22-GB TCM corpus containing approximately 3 million structured entries, a manually validated knowledge graph with more than 200,000 entities, and retrieval-augmented generation for literature retrieval and general TCM question answering. The experience-oriented component was trained using approximately 5000 authentic outpatient records from a senior TCM practitioner and 2000 expert-reviewed augmented cases to provide practitioner-specific diagnostic and prescription references. Through standardized interfaces and role-based access, the system supports knowledge retrieval, question answering, structured consultation, and prescription reference for clinicians, patients, and students. In an expert-rated evaluation of 100 TCM knowledge questions, DFGLM-TCM achieved the highest descriptive mean score among the evaluated models (4.48 ± 0.76). In 454 independent pulmonary-nodule cases, the experience-oriented component achieved a prescription-consistency score of 8.95 ± 0.63, exceeding that of the model additionally trained with general TCM knowledge (7.52 ± 0.44). A one-month assessment involving 35 physicians at three primary-care institutions suggested favorable short-term usability and acceptance. These findings highlight the value of separating general TCM knowledge from practitioner-specific experience while coordinating task-oriented training and multi-task services within a unified system, and support further evaluation of DFGLM-TCM as an auxiliary reference tool in broader clinical settings.